Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2014
09/18/2014US20140271554 Reducing Proinflammatory Response
09/18/2014US20140271553 Nutritional Compositions Containing A Peptide Component with Anti-Inflammatory Properties and Uses Thereof
09/18/2014US20140271552 Nutritional Compositions Containing a Peptide Component and Uses Thereof
09/18/2014US20140271549 Use of Antibiotics to Enhance Treatment With Therapeutic Viruses
09/18/2014US20140271547 Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
09/18/2014US20140271544 Combination therapy for treating hcv infection in specific patient subgenotype sub-population
09/18/2014US20140271543 Pyridin-2(1h)-one derivatives as jak inhibitors
09/18/2014US20140271541 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
09/18/2014US20140271540 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3H)-one, Salts thereof And Methods of Using The Same in Combination Therapy
09/18/2014US20140271532 Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
09/18/2014US20140271531 In-Situ Forming Foam for Endoscopic Lung Volume Reduction
09/18/2014US20140271530 Curcuminoid complexes with enhanced stability, solubility and/or bioavailability
09/18/2014US20140271529 Antifungal compositions for the treatment of secondary skin and nail infections
09/18/2014US20140271527 Subcutaneous delivery of polymer conjugates of therapeutic agents
09/18/2014US20140271526 Antimicrobial polyamide compositions and mastitis treatment
09/18/2014US20140271525 Cosmetic compositions
09/18/2014US20140271523 Nitric Oxide Releasing Multifunctional Polymers
09/18/2014US20140271493 (Trimethoxyphenylamino) Pyrimidinyl Formulations
09/18/2014US20140271492 Manufacturing Process for Effervescent Dosage Forms
09/18/2014US20140271489 Polymeric depots for localization of agent to biological sites
09/18/2014US20140271488 Chiral compounds of varying conformational rigidity and methods of synthesis
09/18/2014US20140271487 Prussian blue-inspired constructs for multimodal imaging and therapy
09/18/2014US20140271480 Uses of indole-ketones or indolidones as neuro-protective drugs
09/18/2014US20140271470 Targeted theranostics for metastatic prostate cancer
09/18/2014US20140271466 HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation
09/18/2014US20140271465 Matrix metalloprotease (mmp) targeted agents for imaging and therapy
09/18/2014US20140271460 Highly Active Anti-Neoplastic and Anti-Proliferative Agents
09/18/2014US20140262915 Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
09/18/2014US20140262868 Ceftolozane-tazobactam pharmaceutical compositions
09/18/2014US20140261454 Tinted antiseptic solutions having improved stability
09/18/2014DE102008025893B4 Verfahren zur Herstellung von Fettsäureamiden mit gesättigten, ungesättigten oder Hydroxy-Fettsäuren Process for the preparation of fatty acid amides with saturated, unsaturated or hydroxy fatty acids
09/17/2014EP2778167A1 Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
09/17/2014EP2778166A1 Thioxanthene derivatives for the treatment of infectious diseases
09/17/2014EP2778159A1 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
09/17/2014EP2778156A1 Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
09/17/2014EP2778155A1 2-aminopyridine derivatives useful as kinase inhibitors
09/17/2014EP2777715A1 Particles comprising luminescent lanthanide complexes
09/17/2014EP2777713A1 Polyethylene glycol-amino acid oligopeptide-irinotecan drug conjugate and drug composition thereof
09/17/2014EP2777707A1 Method of Treating Brain Tumors
09/17/2014EP2777706A1 Methods for increasing the production or activity of catalase
09/17/2014EP2777705A1 Ceftolozane antibiotic compositions
09/17/2014EP2777704A2 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
09/17/2014EP2777703A1 Compositions and methods for enhancing the therapeutic potential of stem cells
09/17/2014EP2777702A1 Stabilized pharmaceutical formulations comprising antineoplastic compounds
09/17/2014EP2777701A1 Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid
09/17/2014EP2777700A1 Method for ingesting creatine composition, creatine composition for use in said ingestion method, and creatine-containing medicinal agent and food each produced using said creatine composition
09/17/2014EP2777699A1 Use of 2,5-dihydroxbencene sulfonic acid (dobesilate) for the treatment of age-related macular degeneration
09/17/2014EP2777698A1 Compositions for Treating Hearing Loss
09/17/2014EP2777696A1 Preparation of stable pharmaceutical dosage forms
09/17/2014EP2777693A1 Biodegradable ocular implants with long-term release characteristics
09/17/2014EP2777404A1 Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women
09/17/2014EP2777403A1 Use of specific carbohydrate systems during pregnancy for improving bone development and formation and/or for improving cognitive and cns development in offspring
09/17/2014EP2776565A1 Methods and compositions for treating diseases, disorders or injury of the nervous system
09/17/2014EP2776563A1 Compounds for the modulation of smn2 splicing
09/17/2014EP2776472A1 Method for preparing glucans from aspergillus niger
09/17/2014EP2776449A2 PROCESS FOR THE PREPARATION OF beta-C-ARYL GLUCOSIDES
09/17/2014EP2776445A1 Therapeutically active thiazolo-pyrimidine derivatives
09/17/2014EP2776444A1 Dihydropteridinones
09/17/2014EP2776442A1 [1, 2, 3]triazolo [4, 5 -d]pyrimidine derivatives as agonists of the cannabinoid receptor 2
09/17/2014EP2776439A1 Purine derivatives for the treatment of viral infections
09/17/2014EP2776438A1 Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections
09/17/2014EP2776437A1 Modulators of opioid receptors and methods of use thereof
09/17/2014EP2776436A1 New compounds
09/17/2014EP2776435A1 Anticancer pyridopyrazines via the inhibition of fgfr kinases
09/17/2014EP2776434A1 Pyridopyrimidinone inhibitors of kinases
09/17/2014EP2776432A1 Aminopyrimidine kinase inhibitors
09/17/2014EP2776431A1 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives
09/17/2014EP2776430A1 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
09/17/2014EP2776429A1 Compounds useful as inhibitors of atr kinase
09/17/2014EP2776427A1 Modulators of atp-binding cassette transporters
09/17/2014EP2776426A1 New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
09/17/2014EP2776425A1 New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
09/17/2014EP2776424A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-cyclic group as vanilloid receptor ligands
09/17/2014EP2776422A1 Compounds useful as inhibitors of atr kinase
09/17/2014EP2776421A1 Compounds useful as inhibitors of atr kinase
09/17/2014EP2776420A1 Pyrazine compounds useful as inhibitors of atr kinase
09/17/2014EP2776419A1 Pyrazine compounds useful as inhibitors of atr kinase
09/17/2014EP2776418A1 Inhibitors of phosphodiesterase type 10a
09/17/2014EP2776417A1 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
09/17/2014EP2776416A1 Pharmaceutical compounds
09/17/2014EP2776413A1 TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
09/17/2014EP2776411A1 Modulators of c3a receptors
09/17/2014EP2776410A1 Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
09/17/2014EP2776407A1 Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
09/17/2014EP2776406A2 Erlotinib salts
09/17/2014EP2776405A1 2-thiopyrimidinones
09/17/2014EP2776404A1 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase
09/17/2014EP2776403A1 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators
09/17/2014EP2776402A1 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
09/17/2014EP2776401A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands
09/17/2014EP2776400A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a co-containing group as vanilloid receptor ligands
09/17/2014EP2776399A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands
09/17/2014EP2776398A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands
09/17/2014EP2776397A1 Quinolines as fgfr kinase modulators
09/17/2014EP2776396A2 Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
09/17/2014EP2776394A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
09/17/2014EP2776393A1 Nampt inhibitors
09/17/2014EP2776387A1 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
09/17/2014EP2776130A1 A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
09/17/2014EP2776066A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
1 ... 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 ... 7860